Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Breast Cancer Res Treat
; 163(3): 635, 2017 06.
Article
en En
| MEDLINE
| ID: mdl-28321586
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Receptores de Estrógenos
Tipo de estudio:
Evaluation_studies
/
Health_economic_evaluation
Límite:
Female
/
Humans
Idioma:
En
Año:
2017
Tipo del documento:
Article